About the Company
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRNB News
Hedge Funds Keep Buying Principia Biopharma Inc. (PRNB)
With this in mind, let’s examine the smart money sentiment towards Principia Biopharma Inc. (NASDAQ:PRNB) and determine whether hedge funds skillfully traded this stock. Video: Watch our video ...
Sanofi to Acquire Principia Biopharma for $3.7 billion; Analysts Optimistic on Outlook
Principia Biopharma stock forecast Six analysts forecast the average price in 12 months at $112.83 with a high forecast of $130.00 and a low forecast of $100.00.
Investors put skin in Peninsula biotech's psoriasis game, and it delivers results
Alumis' target is TYK2, or tyrosine kinase 2, a central player in immune signaling and inflammatory signaling pathways.
Sanofi Agrees to Pay $2.9 Billion For Provention Bio
The acquisition would be Sanofi’s biggest since the purchase of Principia Biopharma Inc. for more than $3 billion in 2020. Sanofi would get a new medicine to complement a handful of its older ...
Sanofi to buy US drugmaker in US$3.4bil deal
PARIS: Sanofi plans to acquire San Francisco, California-based Principia Biopharma Inc in a deal with an enterprise value of US$3.4bil as the French drugmaker pivots toward innovative therapies to ...
Dow Futures, Barrick Gold, Sanofi, Principia Biopharma - 5 Things You Must Know Monday
Wall Street is coming off its third straight week of gains; Sanofi to acquire U.S. biotech Principia Biopharma; Warren Buffett builds a position in Barrick Gold. Stock futures pointed higher ...
Biopharma company to create 401 jobs in Wilson
The jobs would be part of a $371 million investment in Wilson County. The announcement came during a meeting of the state ...
Principia vs. Norwood
Principia's Dasia Scott (21) goes up for a layup during a girls Class 2 semifinal game on March 6, 2024 at Mizzou Arena on ...
ABVC BioPharma Inc ABVC
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Nexien BioPharma Inc NXEN
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
MORGENTHALER VENTURE PARTNERS IX LP's Net Worth
Who is MORGENTHALER VENTURE PARTNERS IX LP? MORGENTHALER VENTURE PARTNERS IX LP has an estimated net worth of $210 Million. This is based on reported shares across multiple companies, which ...
Loading the latest forecasts...